Table 1 Baseline demographics and clinical characteristics.
Bevacizumab group (n = 37) | PRP group (n = 36) | P value | |
|---|---|---|---|
Age (mean ± SD, years) | 51.8 ± 8.9 | 57.1 ± 11.3 | 0.029 |
Sex (male, %) | 17 (45.9) | 20 (55.6) | 0.412 |
Laterality (right, %) | 20 (54.1) | 17 (47.2) | 0.559 |
Lens status (phakic, %) | 30 (81.1) | 30 (83.3) | 0.801 |
Baseline BCVA (mean ± SD, logMAR) | 0.06 ± 0.09 | 0.09 ± 0.11 | 0.111 |
Spherical equivalent (mean ± SD, diopters) | − 0.53 ± 1.35 | − 1.29 ± 1.94 | 0.057 |
Intraocular pressure (mean ± SD, mmHg) | 14.1 ± 3.3 | 13.5 ± 3.5 | 0.696 |
Duration of T2DM (mean ± SD, years) | 8.9 ± 6.1 | 11.2 ± 6.6 | 0.125 |
HbA1c level (mean ± SD, %) | 8.9 ± 2.3 | 8.1 ± 1.9 | 0.098 |
